Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease.
about
The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver DiseasesProtein Kinases and Parkinson's DiseaseBile Acids in Neurodegenerative DisordersParkinson's disease-implicated kinases in the brain; insights into disease pathogenesis.Administration of Tauroursodeoxycholic Acid Attenuates Early Brain Injury via Akt Pathway ActivationSuppression of glia maturation factor expression prevents 1-methyl-4-phenylpyridinium (MPP⁺)-induced loss of mesencephalic dopaminergic neuronsUrsocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease.Mitochondria: key players in the neurotoxic effects of amphetamines.Bile Acids Reduce Prion Conversion, Reduce Neuronal Loss, and Prolong Male Survival in Models of Prion Disease.UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo.Controlled delivery of tauroursodeoxycholic acid from biodegradable microspheres slows retinal degeneration and vision loss in P23H rats.Obesity surgery: happy with less or eternally hungry?Tauroursodeoxycholic acid reduces ER stress by regulating of Akt-dependent cellular prion protein.Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy.The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.The therapeutic potential of chemical chaperones in protein folding diseases.Application of Tauroursodeoxycholic Acid for Treatment of Neurological and Non-neurological Diseases: Is There a Potential for Treating Traumatic Brain Injury?Tauroursodeoxycholic acid: more than just a neuroprotective bile conjugate.Critical Role of Endoplasmic Reticulum Stress in Chronic Intermittent Hypoxia-Induced Deficits in Synaptic Plasticity and Long-Term MemoryNeurotoxin mechanisms and processes relevant to Parkinson's disease: an update.Mass spectrometry-based metabolomics: Targeting the crosstalk between gut microbiota and brain in neurodegenerative disorders.Translational approaches to restoring mitochondrial function in Parkinson's disease.Tauroursodeoxycholic Acid Protects Against Mitochondrial Dysfunction and Cell Death via Mitophagy in Human Neuroblastoma Cells.TGFβ Contributes to the Anti-inflammatory Effects of Tauroursodeoxycholic Acid on an Animal Model of Acute Neuroinflammation.TUDCA: An Agonist of the Bile Acid Receptor GPBAR1/TGR5 With Anti-Inflammatory Effects in Microglial Cells.The association between HSD3B7 gene variant and Parkinson's disease in ethnic Chinese.Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson’s Disease.High Dose and Delayed Treatment with Bile Acids Ineffective in RML Prion-Infected Mice
P2860
Q27026087-5A6B142D-4C83-46B8-A6A6-B05066D3CF24Q28067636-91FA4887-279C-4868-9473-58951A9BF6E1Q28078549-0B822F7D-D685-42FA-BE24-F78D61BE2DCFQ33797449-3031B2C1-A8EE-40D6-AEC0-77CE18163CC7Q33875231-C8CB6D3B-8207-4BED-9F08-734F5AA3E635Q34183725-30CD91B6-9C42-4170-8DAC-B975789B51A6Q34977478-AF1BC2CA-B01F-4BB5-9DE2-8709F9722FE5Q35572468-1B675D6F-3DDD-49A2-B8AB-A1EAB29FF36DQ35861134-2C8A6E6E-9220-432C-964F-50B219811070Q36027872-D75B3A4F-D8D7-4310-AF35-FFFCB3A8D601Q36380667-F49006B6-9B08-4802-A50A-E5EDA06B0352Q36589260-FAB3B205-9335-46CF-85C5-A08456ACA8BEQ37526157-5A571D7B-7C6F-43AD-A746-03D2A3DF88B7Q37596791-F6B82A26-E91C-44A8-B907-B118694B3413Q38175044-2CC3EF2C-B4BC-48EB-92FA-43ABC5FE57B5Q38211124-72FB5595-F2D1-41AA-8FCE-F1B9B747D494Q38694174-AC469A5B-2807-4BF1-BAE3-8BA8B369A3ABQ42043026-47A4088B-A612-4845-8CF9-23901EBEA195Q42217838-CDC9106E-F740-4158-BA16-A6CE7F811F2DQ43679571-942E4899-8102-47B2-B8CE-64F44C50EDE4Q47972723-7C1F5EEE-943F-494D-BBDB-164A35582F9CQ48232790-5C39BB4A-BC9E-49AD-8A86-7CC8E1903AE7Q48282700-AF127E1A-38CE-49DC-B1BF-86D001F9FB92Q48299950-8D79BD3E-CF3A-4B2F-9416-6B1F0C3EF17DQ48392414-1CA96CE7-2209-436F-BE91-B59948B70782Q54941173-6251D065-4F74-4ADF-A256-E1973223D827Q55226753-E7813EAF-F970-4530-97B5-EDAAFCC76592Q57113939-6E0B40E5-FEBE-4A84-BF3A-E3161E83A4F8
P2860
Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Tauroursodeoxycholic acid prev ...... model of Parkinson's disease.
@en
Tauroursodeoxycholic acid prev ...... model of Parkinson's disease.
@nl
type
label
Tauroursodeoxycholic acid prev ...... model of Parkinson's disease.
@en
Tauroursodeoxycholic acid prev ...... model of Parkinson's disease.
@nl
prefLabel
Tauroursodeoxycholic acid prev ...... model of Parkinson's disease.
@en
Tauroursodeoxycholic acid prev ...... model of Parkinson's disease.
@nl
P2860
P50
P1476
Tauroursodeoxycholic acid prev ...... model of Parkinson's disease.
@en
P2093
A Neves Carvalho
C M P Rodrigues
P2860
P2888
P304
P356
10.1007/S12035-012-8295-4
P577
2012-07-08T00:00:00Z